Related Experiment Video
Updated: Aug 24, 2025
High-Resolution Cardiac Positron Emission Tomography/Computed Tomography for Small Animals
Published on: December 16, 2022
Nuclear Molecular Imaging of Disease Burden and Response to Treatment for Cardiac Amyloidosis
Min Zhao1,2,3, Raffaella Calabretta2, Josef Yu2
1Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha 410008, China.
Abstract:
Cardiac amyloidosis (CA) is a heterogeneous group of diseases in which extracellular insoluble amyloid proteins are deposited in specific organs and tissues locally or systemically, thereby interfering with physiological function. Transthyretin protein (TTR) and light chain (AL) amyloidosis are the most common types of cardiac amyloidosis. Radionuclide bone scintigraphy has recently become the most common non-invasive test for the diagnosis of TTR-CA but is of limited value for the diagnosis of AL-CA. PET has proved promising for the diagnosis of CA and its applications are expected to expand in the future. This review summarizes the current bone scintigraphy and amyloid-targeting Positron emission tomography (PET) imaging, the binding imaging properties of radiotracers, and the values of diagnosis, prognosis, and monitoring therapy response in CA.
Insights
Cardiac amyloidosis diagnosis is evolving. While bone scintigraphy aids transthyretin amyloidosis detection, positron emission tomography (PET) shows promise for broader cardiac amyloidosis imaging and therapy monitoring.
Area of Science:
- Nuclear medicine
- Cardiology
- Radiology
Background:
- Cardiac amyloidosis (CA) involves amyloid protein deposition in the heart, impairing function.
- Transthyretin (TTR) and light chain (AL) amyloidosis are the primary forms of CA.
- Current diagnostic tools have limitations, particularly for AL-CA.
Purpose of the Study:
- To review current imaging techniques for cardiac amyloidosis.
- To discuss the role of bone scintigraphy and positron emission tomography (PET) in CA diagnosis.
- To evaluate radiotracer properties and their utility in diagnosis, prognosis, and therapy monitoring.
Main Methods:
- Review of current literature on bone scintigraphy and PET imaging in CA.
- Analysis of radiotracer binding properties.
- Evaluation of diagnostic, prognostic, and therapeutic monitoring applications.
Main Results:
- Bone scintigraphy is effective for diagnosing TTR-CA but less so for AL-CA.
- PET imaging demonstrates significant promise for CA diagnosis, with expanding applications.
- Radiotracers are crucial for assessing CA and response to treatment.
Conclusions:
- Advanced imaging, particularly PET, is crucial for comprehensive cardiac amyloidosis management.
- PET offers a promising future for diagnosing, prognosing, and monitoring CA.
- Further research into novel radiotracers will enhance CA patient care.
Related Concept Videos
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
01:28Imaging Studies for Cardiovascular System V: CT
01:25Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
01:20Imaging Studies for Cardiovascular System III: X-Ray
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:29Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...